Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Treatment guideline
Vitiligo is a non-lethal, non-communicable, immune-mediated and generally progressive skin disease that creates milky white patches of irregular shape on the skin. A specific type of leukoderma, vitiligo is the most common form of pigmentary disorders, equally affecting all races, age groups and social strata.
The ethiopathogenesis is complex and involves the interplay of multiple factors; however, the exact pathogenesis is not well known. Other than the appearance of the spots and occasional itchiness, vitiligo does not cause any discomfort, irritation, soreness, or dryness of the skin. Vitiligo has negative and often devastating effect on the quality of patients’ lives and their socio-economic status.
Vitiligo prevalence is estimated at 0.76% of the diagnosed U.S. population, or 1.11% including 40% of those with the condition being undiagnosed, according to the recent study.
Worldwide prevalence estimates of vitiligo vary widely, ranging from 0.004% to 2.28% and even higher in certain regions. However, these estimates are outdated, as most studies did not include those with undiagnosed vitiligo or were extrapolated from other studies.
There are two major types of vitiligo:
- Segmental, also called unilateral vitiligo, happens on one part of the body. It often starts at a young age and usually stops spreading after a year.
- Non-segmental, also called bilateral or generalized vitiligo, may appear on all body parts, especially areas that are bumped or rubbed frequently. These patches often extend slowly over time if left untreated.
An early distinction between these two basic types of vitiligo is very important in predicting disease activity and choosing the right treatment.
FAQOther Questions
- Which is better for judging vitiligo — Wood’s lamp or dermoscopy?
A recent study out of India compared the two head-to-head. Both tools correlated fairly well with clinical criteria, but dermoscopy had a slight edge: Wood’s lamp: sensitivit...
- Белые пятна на теле? Витилиго?
Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что прои...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.